AGIO vs MIRM
AGIO: A commercial-stage biopharmaceutical company focused on transforming the treatment landscape for rare genetic hematologic diseases through its innovative pyruvate kinase activator technology. MIRM: Mirum is a rare disease biopharmaceutical company commercializing approved bile acid and hepatic therapies while advancing late-stage candidates in cholestatic liver disease and viral hepatitis.
Side-by-side fundamentals
| Metric | AGIO | MIRM | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $36.05 | $114.48 | |
| Market cap as of 2026-07-23 | $2.2B | $7.0B | |
| PEG as of 2026-07-23 | n/a | -0.01 | |
| Net margin as of 2026-07-23 | -639.8% | -140.2% | MIRM higher |
| Gross margin as of 2026-07-23 | +90.0% | +81.4% | AGIO higher |
| Operating margin as of 2026-07-23 | -720.0% | -139.8% | MIRM higher |
| ROE as of 2026-07-23 | -34.1% | -289.3% | AGIO higher |
| ROA as of 2026-07-23 | -31.7% | -98.5% | AGIO higher |
| Debt / equity as of 2026-07-23 | 0.00 | 1.28 | AGIO lower |
| Revenue growth (YoY) as of 2026-07-23 | +78.3% | +50.2% | AGIO higher |
| Revenue CAGR (3y) SEC XBRL | +56.0% | +89.1% | MIRM higher |
| Beta as of 2026-07-23 | 0.58 | 0.51 | |
| 1-year return as of 2026-07-22 close | -6.4% | +119.4% | MIRM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.